Drug class
Non-nitrogen-containing bisphosphonate; antiresorptive agent
Mechanism of action
Binds to bone mineral and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation/dissolution, reducing bone turnover.
General use cases
- Management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast carcinoma or multiple myeloma; the exact formulation and indication are product-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
